Intrinsic Value of S&P & Nasdaq Contact Us

Karuna Therapeutics, Inc. KRTX NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
27/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$257.50
-21.9%

Financial Health Score — KRTX

Karuna Therapeutics, Inc. (KRTX) has an overall financial health rating of B with a composite score of 0 out of 5.

This suggests the company faces some financial challenges worth monitoring. Rating as of 2024-03-15.

B
Overall Rating
2024-03-15

Rating History

Date Rating DCF ROE ROA D/E P/E P/B
2024-03-15 B -/5 -/5 -/5 -/5 -/5 -/5
2024-03-14 B -/5 -/5 -/5 -/5 -/5 -/5
2024-03-13 B -/5 -/5 -/5 -/5 -/5 -/5
2024-03-12 B -/5 -/5 -/5 -/5 -/5 -/5
2024-03-11 B -/5 -/5 -/5 -/5 -/5 -/5
2024-03-07 B -/5 -/5 -/5 -/5 -/5 -/5
2024-03-06 B -/5 -/5 -/5 -/5 -/5 -/5
2024-03-05 B -/5 -/5 -/5 -/5 -/5 -/5
2024-03-04 B -/5 -/5 -/5 -/5 -/5 -/5
2024-03-01 B -/5 -/5 -/5 -/5 -/5 -/5
2024-02-29 B -/5 -/5 -/5 -/5 -/5 -/5
2024-02-28 B -/5 -/5 -/5 -/5 -/5 -/5
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message